DE602005024599D1 - Verbindungen modulierende thrombopoietinaktivität und verfahren - Google Patents
Verbindungen modulierende thrombopoietinaktivität und verfahrenInfo
- Publication number
- DE602005024599D1 DE602005024599D1 DE602005024599T DE602005024599T DE602005024599D1 DE 602005024599 D1 DE602005024599 D1 DE 602005024599D1 DE 602005024599 T DE602005024599 T DE 602005024599T DE 602005024599 T DE602005024599 T DE 602005024599T DE 602005024599 D1 DE602005024599 D1 DE 602005024599D1
- Authority
- DE
- Germany
- Prior art keywords
- thrombopoietinactivity
- compounds modulating
- modulating
- compounds
- modulating thrombopoietinactivity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/04—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62187904P | 2004-10-25 | 2004-10-25 | |
US67500105P | 2005-04-25 | 2005-04-25 | |
PCT/US2005/038055 WO2006047344A1 (en) | 2004-10-25 | 2005-10-21 | Thrombopoietin activity modulating compounds and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602005024599D1 true DE602005024599D1 (de) | 2010-12-16 |
Family
ID=35610075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602005024599T Active DE602005024599D1 (de) | 2004-10-25 | 2005-10-21 | Verbindungen modulierende thrombopoietinaktivität und verfahren |
Country Status (15)
Country | Link |
---|---|
US (3) | US7314887B2 (de) |
EP (1) | EP1805155B1 (de) |
JP (1) | JP4728340B2 (de) |
KR (1) | KR100958337B1 (de) |
AR (1) | AR051940A1 (de) |
AT (1) | ATE486859T1 (de) |
AU (1) | AU2005299720B2 (de) |
BR (1) | BRPI0516883A (de) |
CA (1) | CA2583764C (de) |
DE (1) | DE602005024599D1 (de) |
IL (2) | IL182763A (de) |
MX (1) | MX2007004765A (de) |
NO (1) | NO20072199L (de) |
NZ (1) | NZ554662A (de) |
WO (1) | WO2006047344A1 (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CY2010012I2 (el) * | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
WO2005118551A2 (en) * | 2004-05-28 | 2005-12-15 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
AU2005299720B2 (en) * | 2004-10-25 | 2010-02-04 | Ligand Pharmaceuticals Incorporated | Thrombopoietin activity modulating compounds and methods |
AU2006318527A1 (en) * | 2005-11-23 | 2007-05-31 | Ligand Pharmaceuticals Incorporated | Thrombopoietin activity modulating compounds and methods |
EP2086551A4 (de) * | 2006-12-01 | 2011-06-08 | Stategics Inc | Thrombopoietin-mimetika |
US20090304634A1 (en) * | 2006-12-12 | 2009-12-10 | Smithkline Beecham Corporation | Novel Combinations |
WO2008074078A1 (en) * | 2006-12-19 | 2008-06-26 | University Of Wollongong | Selectively deliverable isatin-based cytotoxic agents |
UY30915A1 (es) | 2007-02-16 | 2008-09-02 | Smithkline Beecham Corp | Método de tratamiento de canceres |
US20110129550A1 (en) * | 2007-02-16 | 2011-06-02 | Connie Erickson-Miller | Cancer treatment method |
US20110160130A1 (en) * | 2007-02-16 | 2011-06-30 | Connie Erickson-Miller | Cancer treatment method |
MX2010003881A (es) * | 2007-10-09 | 2010-07-28 | Univ Pennsylvania | El agonista del receptor de trombopoyetina (tpora) destruye las celulas de leucemia mieloide aguda de humano. |
WO2009140464A1 (en) * | 2008-05-16 | 2009-11-19 | Ligand Pharmaceuticals, Inc. | Methods of administration of thrombopoietin mimetic compounds |
US8476249B2 (en) | 2009-05-07 | 2013-07-02 | Glaxosmithkline Llc | Method of treating thrombocytopenia |
US8680150B2 (en) * | 2009-05-28 | 2014-03-25 | Ligand Pharmaceuticals, Inc. | Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors |
WO2013074459A1 (en) * | 2011-11-14 | 2013-05-23 | Ligand Pharmaceuticals, Inc. | Methods and compositions associated with the granulocyte colony-stimulating factor receptor |
US9962370B2 (en) | 2013-03-15 | 2018-05-08 | Ligand Pharmaceuticals Incorporated | Methods of treatment associated with the granulocyte colony-stimulating factor receptor |
CA2927806C (en) | 2013-11-27 | 2023-01-10 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
CN106632407A (zh) * | 2016-09-30 | 2017-05-10 | 陕西科技大学 | 一种具抗肿瘤活性的不对称双7‑n杂靛红席夫碱类化合物的合成方法 |
MX2021012679A (es) * | 2019-04-17 | 2021-11-12 | Colorado Res Partners Llc | Nuevos compuestos y metodos de uso para el tratamiento de enfermedades o trastornos relacionados con la fructosa. |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE653800A (de) | ||||
DE193633C (de) | ||||
US3148192A (en) * | 1961-06-27 | 1964-09-08 | Roussel Uclaf | Halogenated 20alpha-yohimbane compounds |
DE450819C (de) | 1924-12-24 | 1927-10-20 | Chemische Ind Ges | Verfahren zur Herstellung von chromhaltigen Azofarbstoffen |
GB252957A (en) * | 1926-02-19 | 1926-06-10 | Chem Fab Vormals Sandoz | Manufacture of diazotizable azo-dyestuffs and intermediate products therefor |
GB898706A (en) * | 1957-09-20 | 1962-06-14 | Polaroid Corp | Azo dyes derived from dihydroxyphenyl ketones and their use in photography |
BE594503A (de) * | 1959-08-29 | |||
GB1080864A (en) | 1963-02-26 | 1967-08-23 | Ici Ltd | Five membered heterocyclic systems and their use as fungicides |
GB1269781A (en) * | 1968-11-12 | 1972-04-06 | Ici Ltd | Alkanolamine derivatives |
US3966900A (en) * | 1969-03-12 | 1976-06-29 | Airwick Industries, Inc. | Evaporator system comprising a stabilized pesticidal phosphoric acid ester and method for stabilizing such ester enclosed in an evaporator |
US3754857A (en) * | 1969-08-27 | 1973-08-28 | American Cyanamid Co | Polyethylene terephthalate,nylon and organic esters of cellulose dyedwith 5-(2-nitro-pranisylazo) barbituric acid |
EP0034725B1 (de) * | 1980-02-18 | 1984-07-25 | BASF Aktiengesellschaft | Imidazolylmethylgruppen enthaltende Farbstoffe und deren Verwendung |
US4322533A (en) * | 1980-03-17 | 1982-03-30 | Lesher George Y | 1H-Indole-2,3-dione derivatives |
DE3329340A1 (de) | 1983-08-13 | 1985-03-07 | Basf Ag, 6700 Ludwigshafen | Verlackungsmittel enthaltende farbstoffzubereitungen basischer farbstoffe |
DE3434379A1 (de) * | 1984-09-19 | 1986-03-20 | Basf Farben + Fasern Ag, 2000 Hamburg | Pigmentzubereitungen |
GB8431426D0 (en) * | 1984-12-13 | 1985-01-23 | Glaxo Group Ltd | Chemical compounds |
DE3743235A1 (de) * | 1987-12-19 | 1989-06-29 | Bayer Ag | Basische farbstoffe |
DE3810958A1 (de) | 1988-03-31 | 1989-10-12 | Basf Ag | Tinten fuer ink-jet-aufzeichnungsverfahren |
GB8816944D0 (en) * | 1988-07-15 | 1988-08-17 | Sobio Lab | Compounds |
JP2683097B2 (ja) | 1989-04-28 | 1997-11-26 | キヤノン株式会社 | 電子写真感光体 |
US5164404A (en) * | 1991-03-15 | 1992-11-17 | Neurosearch A/S | Hydrazone derivatives and their use |
JP2709750B2 (ja) * | 1991-03-27 | 1998-02-04 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料 |
US5298658A (en) * | 1991-12-20 | 1994-03-29 | E. I. Du Pont De Nemours And Company | Photographic elements with reduced print-through |
DE4335623A1 (de) | 1993-10-19 | 1995-04-20 | Henkel Kgaa | Indolinon-Derivate zum Färben keratinhaltiger Fasern |
US5482546A (en) * | 1994-03-30 | 1996-01-09 | Canon Kabushiki Kaisha | Dye, ink containing the same, and ink-jet recording method and instrument using the ink |
CA2167090C (en) | 1994-03-31 | 2002-05-14 | Timothy D. Bartley | Compositions and methods for stimulating megakaryocyte growth and differentiation |
US6184363B1 (en) * | 1997-06-13 | 2001-02-06 | Northwestern University | Inhibitors of β-lactamases and uses therefor |
US6075044A (en) * | 1997-07-21 | 2000-06-13 | The Regents Of The University Of California | Heterocyclic derivatives as inhibitors of purine salvage phosphoribosyltransferases |
GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
US6649631B1 (en) * | 1997-10-23 | 2003-11-18 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating bone deficit conditions |
GC0000177A (en) * | 1998-12-17 | 2006-03-29 | Smithkline Beecham | Thrombopoietin mimetics |
JP2000206645A (ja) | 1999-01-18 | 2000-07-28 | Fuji Photo Film Co Ltd | 画像形成材料および画像形成方法 |
GB9904933D0 (en) * | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
CN1376150A (zh) * | 1999-07-26 | 2002-10-23 | 盐野义制药株式会社 | 具有血栓形成素受体拮抗作用的药物组合物 |
EP1213965B1 (de) | 1999-09-10 | 2006-01-18 | Smithkline Beecham Corporation | Thrombopoietin-mimetika |
WO2001021180A1 (en) | 1999-09-24 | 2001-03-29 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
US6720345B1 (en) * | 1999-11-05 | 2004-04-13 | Smithkline Beecham Corporation | Semicarbazone derivatives and their use as thrombopoietin mimetics |
JP2001152055A (ja) | 1999-11-26 | 2001-06-05 | Fuji Photo Film Co Ltd | インクジェット記録用インクおよびそれを用いた画像記録方法 |
CY2010012I2 (el) * | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
JP4359382B2 (ja) | 2000-07-11 | 2009-11-04 | 富士フイルム株式会社 | 新規なヒドラゾン色素 |
US6964977B2 (en) * | 2000-09-01 | 2005-11-15 | Smithkline Beecham Corporation | Oxindole derivatives |
AU2001288374A1 (en) * | 2000-09-01 | 2002-03-22 | Glaxo Group Limited | Substituted oxindole derivatives as tyrosine kinase inhibitors |
US6642265B1 (en) * | 2000-09-08 | 2003-11-04 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
JP2002129073A (ja) | 2000-10-20 | 2002-05-09 | Fuji Photo Film Co Ltd | 油性インク組成物 |
JP2002129072A (ja) | 2000-10-20 | 2002-05-09 | Fuji Photo Film Co Ltd | インクジェット記録用インク及びそれを用いた画像記録方法 |
AU2002239718A1 (en) * | 2000-12-19 | 2002-07-01 | Ligand Pharmaceuticals | Thrombopoietin mimetics |
ATE384076T1 (de) * | 2000-12-21 | 2008-02-15 | Smithkline Beecham Corp | Regulierte aktivierung von zellmembranrezeptoren durch metallchelatisierende agonisten |
JP4145654B2 (ja) * | 2001-01-26 | 2008-09-03 | 塩野義製薬株式会社 | トロンボポエチン受容体アゴニスト作用を有する環状化合物 |
US6875786B2 (en) * | 2001-03-01 | 2005-04-05 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
CA2439263C (en) * | 2001-03-02 | 2012-10-23 | Frank Becker | Three hybrid assay system |
GB0106343D0 (en) * | 2001-03-14 | 2001-05-02 | Avecia Ltd | Compounds compositions and processes |
IL160010A0 (en) * | 2001-07-23 | 2004-06-20 | Univ Ramot | Methods and compositions for treating fungal infections |
WO2003011287A1 (en) * | 2001-08-03 | 2003-02-13 | Vertex Pharmaceuticals Incorporated | Pyrazolon derivatives as inhibitors of gsk-3 |
JP2003128946A (ja) | 2001-10-26 | 2003-05-08 | Fuji Photo Film Co Ltd | 新規なアゾ色素、及び該アゾ色素の互変異性体 |
GB0126036D0 (en) | 2001-10-30 | 2001-12-19 | Amedis Pharm Ltd | Silicon compounds |
SI1466912T1 (sl) * | 2002-01-18 | 2013-08-30 | Astellas Pharma Inc. | Derivat 2-acilaminotiazola ali njegova sol |
US20050049267A1 (en) * | 2002-03-01 | 2005-03-03 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
CN1652770A (zh) | 2002-03-29 | 2005-08-10 | 利兰·斯坦福青年大学托管委员会 | 使用抑制素和其它免疫调节剂治疗自身免疫病 |
US20030229453A1 (en) * | 2002-04-09 | 2003-12-11 | Antonysamy Stephen Suresh | Crystals and structures of PAK4KD kinase PAK4KD |
JP2003313450A (ja) | 2002-04-22 | 2003-11-06 | Fuji Photo Film Co Ltd | アゾ色素及びその互変異性体 |
JP2003335972A (ja) | 2002-05-21 | 2003-11-28 | Fuji Photo Film Co Ltd | アゾ化合物及びその製造方法 |
TWI280128B (en) * | 2002-05-22 | 2007-05-01 | Smithkline Beecham Corp | 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
US7414040B2 (en) * | 2002-06-06 | 2008-08-19 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
TWI324593B (en) * | 2002-10-09 | 2010-05-11 | Nissan Chemical Ind Ltd | Pyrazolone compounds and thrombopoietin receptor activator |
JP2004143118A (ja) | 2002-10-28 | 2004-05-20 | Fuji Photo Film Co Ltd | アゾ化合物及びその互変異性体、並びに、その製造方法 |
US20060084682A1 (en) * | 2002-12-13 | 2006-04-20 | Heerding Dirk A | Thrombopoietin mimetics |
US20040253178A1 (en) * | 2002-12-20 | 2004-12-16 | Shane Atwell | Crystals and structures of spleen tyrosine kinase SYKKD |
JP4895807B2 (ja) * | 2003-04-29 | 2012-03-14 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 変性疾患/損傷の治療方法 |
EP1638487A2 (de) * | 2003-05-28 | 2006-03-29 | Medcool, Inc. | Verfahren und geräte für die wärmeaktivierung einer konsole eines wärmeabgabesystems |
UA82695C2 (uk) * | 2003-06-06 | 2008-05-12 | Нисан Кемикал Индастриз, Лтд. | Гетероароматичні сполуки як активатори рецептора тромбопоетину |
EP1755574A4 (de) | 2004-04-06 | 2009-05-13 | Semafore Pharmaceuticals Inc | Pten-inhibitoren |
EP1746887A1 (de) | 2004-05-12 | 2007-01-31 | Bayer CropScience GmbH | Regulierung des pflanzenwachstums |
WO2005118551A2 (en) | 2004-05-28 | 2005-12-15 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
SE0401790D0 (sv) | 2004-07-07 | 2004-07-07 | Forskarpatent I Syd Ab | Tamoxifen response in pre- and postmenopausal breast cancer patients |
AU2005299720B2 (en) | 2004-10-25 | 2010-02-04 | Ligand Pharmaceuticals Incorporated | Thrombopoietin activity modulating compounds and methods |
GT200500321A (es) | 2004-11-09 | 2006-09-04 | Compuestos y composiciones como inhibidores de proteina kinase. | |
US7563781B2 (en) | 2005-01-14 | 2009-07-21 | Janssen Pharmaceutica Nv | Triazolopyrimidine derivatives |
AU2006318527A1 (en) | 2005-11-23 | 2007-05-31 | Ligand Pharmaceuticals Incorporated | Thrombopoietin activity modulating compounds and methods |
WO2007114972A2 (en) | 2006-01-11 | 2007-10-11 | Elifecare Enterprises, Inc | Toolbar user interface for information system |
-
2005
- 2005-10-21 AU AU2005299720A patent/AU2005299720B2/en not_active Ceased
- 2005-10-21 AT AT05813834T patent/ATE486859T1/de not_active IP Right Cessation
- 2005-10-21 CA CA002583764A patent/CA2583764C/en not_active Expired - Fee Related
- 2005-10-21 WO PCT/US2005/038055 patent/WO2006047344A1/en active Application Filing
- 2005-10-21 EP EP05813834A patent/EP1805155B1/de active Active
- 2005-10-21 KR KR1020077011701A patent/KR100958337B1/ko active IP Right Grant
- 2005-10-21 MX MX2007004765A patent/MX2007004765A/es active IP Right Grant
- 2005-10-21 NZ NZ554662A patent/NZ554662A/en not_active IP Right Cessation
- 2005-10-21 JP JP2007538100A patent/JP4728340B2/ja active Active
- 2005-10-21 DE DE602005024599T patent/DE602005024599D1/de active Active
- 2005-10-21 US US11/256,572 patent/US7314887B2/en active Active
- 2005-10-21 BR BRPI0516883-0A patent/BRPI0516883A/pt not_active Application Discontinuation
- 2005-10-25 AR ARP050104466A patent/AR051940A1/es not_active Application Discontinuation
-
2007
- 2007-04-23 IL IL182763A patent/IL182763A/en not_active IP Right Cessation
- 2007-04-27 NO NO20072199A patent/NO20072199L/no not_active Application Discontinuation
- 2007-11-08 US US11/937,392 patent/US7691895B2/en not_active Expired - Fee Related
- 2007-12-21 US US11/963,115 patent/US20080103190A1/en not_active Abandoned
-
2008
- 2008-05-19 IL IL191542A patent/IL191542A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20070084506A (ko) | 2007-08-24 |
AU2005299720B2 (en) | 2010-02-04 |
US20080103190A1 (en) | 2008-05-01 |
AU2005299720A1 (en) | 2006-05-04 |
JP4728340B2 (ja) | 2011-07-20 |
JP2008517932A (ja) | 2008-05-29 |
IL191542A0 (en) | 2008-11-03 |
KR100958337B1 (ko) | 2010-05-17 |
ATE486859T1 (de) | 2010-11-15 |
CA2583764C (en) | 2009-06-09 |
US7314887B2 (en) | 2008-01-01 |
IL182763A (en) | 2010-12-30 |
BRPI0516883A (pt) | 2008-09-23 |
NO20072199L (no) | 2007-06-05 |
NZ554662A (en) | 2008-11-28 |
US20060116417A1 (en) | 2006-06-01 |
AR051940A1 (es) | 2007-02-21 |
IL191542A (en) | 2013-08-29 |
EP1805155A1 (de) | 2007-07-11 |
US20080146594A1 (en) | 2008-06-19 |
EP1805155B1 (de) | 2010-11-03 |
IL182763A0 (en) | 2007-07-24 |
US7691895B2 (en) | 2010-04-06 |
MX2007004765A (es) | 2007-07-09 |
CA2583764A1 (en) | 2006-05-04 |
WO2006047344A1 (en) | 2006-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602005024599D1 (de) | Verbindungen modulierende thrombopoietinaktivität und verfahren | |
DE602006016666D1 (de) | Kommunikationsvorrichtung und Verfahren | |
ATE460403T1 (de) | Verbindungen und verfahren zur modulierung von fx-rezeptoren | |
ATE500824T1 (de) | Verfahren zur reinigung von trans-(-)-delta9- tetrahydrocannabinol und trans-(+)-delta9- tetrahydrocannabinol | |
FI20030046A (fi) | Modulointimenetelmä | |
DE602005014371D1 (de) | Einrichtung und verfahren zur unabhängigen positionierung | |
DE602006010154D1 (de) | Biometrisches System und biometrisches Verfahren | |
DE602005027138D1 (de) | Schnappschuss-System und Verfahren | |
DE602005007551D1 (de) | Nachgiebige Dichtungsanordnung, Sytem und Verfahren | |
DE602006021341D1 (de) | Rauchgasnassentschwefelungsvorrichtung und verfahren zur rauchgasnassentschwefelung | |
ATE518584T1 (de) | Tönungsmaschinensystem und verfahren | |
DE602005001520D1 (de) | Zeiteinstellungssystem und Zeiteinstellungsverfahren | |
DE602004004267D1 (de) | Formtrennmittelzusammensetzung und verfahren damit | |
DE602005014898D1 (de) | Flüssigkeitssensor und Verfahren | |
DE112005002653A5 (de) | Verfahren zur Konfiguration von Feldgeräten | |
DE60333094D1 (de) | Verbindungen, zusammensetzungen und verfahren | |
ATE546994T1 (de) | Steuergerät und verfahren | |
DE602005023445D1 (de) | Malverfahren | |
DE602005026520D1 (de) | Malverfahren | |
ATE394369T1 (de) | Verfahren zur aufreinigung von mesotrion | |
DE602004016281D1 (de) | Verfahren und System zur Speicherverwaltung | |
DE602006013597D1 (de) | Mischvorrichtung und verfahren | |
DE602005014187D1 (de) | Kommunikationssystem und Verfahren | |
DE602006014688D1 (de) | Vorrichtung und verfahren | |
DE112005002649A5 (de) | Verfahren zur Konfiguration von Feldgeräten |